# Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

> **NCT06547151** · PHASE2 · RECRUITING · sponsor: **Amorphical Ltd.** · enrollment: 81 (estimated)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** AMOR-1
- **DRUG:** Crystalline Calcium Carbonate

## Key facts

- **NCT ID:** NCT06547151
- **Lead sponsor:** Amorphical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547151, "Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06547151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*